| Title |
Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, November 2013
|
| DOI | 10.2147/ndt.s38899 |
| Pubmed ID | |
| Authors |
Chuan Zou, Xiang Ding, Joseph H Flaherty, Birong Dong |
| Abstract |
Generalized anxiety disorder (GAD) is a prevalent, disabling disease and is highly comorbid with other psychiatric disorders both in Western countries and the People's Republic of China. Fluoxetine, a selective inhibitor of serotonin reuptake (SSRI), is widely utilized in the management of GAD in clinical practice despite the lack of strong evidence. This article reviews fluoxetine trials to investigate fluoxetine's efficacy and tolerability in Chinese patients with GAD. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 1% |
| Unknown | 81 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 17% |
| Student > Bachelor | 10 | 12% |
| Student > Master | 9 | 11% |
| Student > Ph. D. Student | 6 | 7% |
| Student > Postgraduate | 5 | 6% |
| Other | 11 | 13% |
| Unknown | 27 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Psychology | 3 | 4% |
| Unspecified | 3 | 4% |
| Other | 12 | 15% |
| Unknown | 30 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2013.
All research outputs
#16,720,137
of 25,371,288 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,718
of 3,132 outputs
Outputs of similar age
#136,829
of 226,632 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#24
of 51 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,632 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.